Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy.
about
Inflammatory microenvironment contributes to epithelial-mesenchymal transition in gastric cancerImmunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigationsImmune Checkpoint Blockade to Improve Tumor Infiltrating Lymphocytes for Adoptive Cell Therapy.A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells.Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma.Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors.Immunoscore encompassing CD3+ and CD8+ T cell densities in distant metastasis is a robust prognostic marker for advanced colorectal cancer.Tumor-infiltrating lymphocytes for the treatment of metastatic cancer.Generation of tumor-specific cytotoxic T-lymphocytes from the peripheral blood of colorectal cancer patients for adoptive T-cell transfer.Tumor regulation of the tissue environment in the liver.Immunotherapeutic Strategies for Gastric Carcinoma: A Review of Preclinical and Clinical Recent Development.Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy.Understanding immune phenotypes in human gastric disease tissues by multiplexed immunohistochemistry.Expansion of tumor-infiltrating lymphocytes and their potential for application as adoptive cell transfer therapy in human breast cancer.4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer.PD-L1 expression is a prognostic factor in subgroups of gastric cancer patients stratified according to their levels of CD8 and FOXP3 immune markers.Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy.CD8+ tumor-infiltrating lymphocytes as a novel prognostic biomarker in lung sarcomatoid carcinoma, a rare subtype of lung cancer
P2860
Q26740208-A1071955-CC67-437F-BA9F-A551D66CD4E0Q26781038-E057004C-C970-4AD5-8DB5-A55B060714D5Q35981245-388016A0-2350-446A-A809-6C47A676B7BBQ36943923-0B08B869-11B4-42A4-916C-1437B2BB8E67Q37012537-D53A9FC3-2A6B-4ADB-8A56-84407A8137D1Q37346107-959F0DE8-7170-48CE-959C-C704C92E3F47Q37697218-AE6F295A-6EF0-4340-9FF0-4980FD39C911Q38636573-0AFF46C7-E632-44DD-8F70-52A6D19B0DF1Q38923514-A30ACD46-8209-43A8-81CA-5E405587DB2EQ39123136-00B67D1E-2439-473E-8EE3-5824C481CD35Q41110505-593B3099-3028-4A03-9952-B55B2B377542Q41963078-37A7B2DA-8800-459B-8782-30D007BED70DQ42376660-7A5ECC8D-90B1-439B-9FA0-B3647266B186Q49461096-60C82570-6F1E-4527-B5DB-4D579D2E7B33Q54139665-39720083-EC60-4D08-906E-66B527114254Q55394623-A4B43634-8245-49AE-AA4B-B0FE81B33C16Q55715408-75606DA6-B48B-4624-9E23-4896B02BDA70Q57075029-CA2BEF84-8586-4641-BA01-20A50549ABFE
P2860
Tumor-reactive CD8+ T cells in metastatic gastrointestinal cancer refractory to chemotherapy.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Tumor-reactive CD8+ T cells in ...... er refractory to chemotherapy.
@en
Tumor-reactive CD8+ T cells in ...... er refractory to chemotherapy.
@nl
type
label
Tumor-reactive CD8+ T cells in ...... er refractory to chemotherapy.
@en
Tumor-reactive CD8+ T cells in ...... er refractory to chemotherapy.
@nl
prefLabel
Tumor-reactive CD8+ T cells in ...... er refractory to chemotherapy.
@en
Tumor-reactive CD8+ T cells in ...... er refractory to chemotherapy.
@nl
P2093
P2860
P1476
Tumor-reactive CD8+ T cells in ...... cer refractory to chemotherapy
@en
P2093
Chyi-Chia R Lee
John R Wunderlich
Paul F Robbins
Simon Turcotte
Steven A Rosenberg
P2860
P304
P356
10.1158/1078-0432.CCR-13-1736
P407
P50
P577
2013-11-11T00:00:00Z